Terms: = Liver cancer AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Clinical Outcome
502 results:
1. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract] [Full Text] [Related]
2. COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma.
Liu J; Han D; Xuan J; Xie J; Wang W; Zhou Q; Chen K
Aging (Albany NY); 2024 Mar; 16(6):5264-5287. PubMed ID: 38466642
[TBL] [Abstract] [Full Text] [Related]
3. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract] [Full Text] [Related]
4. Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.
He C; Guo Z; Zhang H; Yang G; Gao J; Mo Z
Aging (Albany NY); 2024 Jan; 16(2):1733-1749. PubMed ID: 38244582
[TBL] [Abstract] [Full Text] [Related]
5. Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.
Xie LL; Huang YB; Dong KR; Yang SB; Shen C; Ma YY
BMC Pediatr; 2024 Jan; 24(1):8. PubMed ID: 38172842
[TBL] [Abstract] [Full Text] [Related]
6. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract] [Full Text] [Related]
7. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of clinical outcome between laparoscopic and open hepatectomy of high difficulty score for hepatocellular carcinoma: a propensity score analysis.
Ng KKC; Cheng KC; Kung JWC; Ho KM; Lok HT; Fung AKY; Chong CCN; Cheung SYS; Lee KF; Wong J; Lai PBS
Surg Endosc; 2024 Feb; 38(2):857-871. PubMed ID: 38082015
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract] [Full Text] [Related]
11. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
Amin MN; El-Far YM; El-Mowafy M; Elgaml A
Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
[TBL] [Abstract] [Full Text] [Related]
12. 10 years, 100 robotic major hepatectomies: a single-center experience.
McCarron F; Cochran A; Ricker A; Mantha R; Driedger M; Beckman M; Vrochides D; Martinie J
Surg Endosc; 2024 Feb; 38(2):902-907. PubMed ID: 37845533
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
14. Transarterial chemoembolization
Yang B; Yuan M; Yang T; Liao Z; Wu H
Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
[TBL] [Abstract] [Full Text] [Related]
15. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract] [Full Text] [Related]
16. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
17. clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract] [Full Text] [Related]
18. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
Zou L; Liu K; Shi Y; Li G; Li H; Zhao C
Cancer Biomark; 2023; 36(4):299-311. PubMed ID: 36938729
[TBL] [Abstract] [Full Text] [Related]
19. [Sero-epidemiological characteristics of the hepatitis D virus infection among hepatitis B virus infected-patients at a single center in Xinjiang region].
Zheng RJ; Talafu T; Deng ZR; Han D; Pan KJ; Lu XB
Zhonghua Gan Zang Bing Za Zhi; 2022 Oct; 30(10):1044-1049. PubMed ID: 36727249
[No Abstract] [Full Text] [Related]
20. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract] [Full Text] [Related]
[Next]